Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
Ann Otol Rhinol Laryngol ; 132(12): 1686-1689, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37243327

ABSTRACT

INTRODUCTION: Aminoglycoside antibiotics such as gentamicin are bactericidal and effective against gram negative organisms and act synergistically against gram positive organisms, including Staphylococcus aureus. However, they have serious adverse effects such as nephrotoxicity and ototoxicity. Gentamicin ototoxicity may occur after a single dose and results in decreased vestibular function, which is frequently debilitating and often permanent. OBJECTIVE: To emphasize the risk of gentamicin ototoxicity and suggest alternative antibiotics in penicillin-allergic patients undergoing surgery. CASE SUMMARY: We present a case of a woman with preexisting Meniere's Disease who received gentamicin 400 mg perioperatively for a sigmoidectomy due to a penicillin allergy listed in the patient's medical record. The patient developed severe ototoxicity preventing her from working or driving. Physical examination was remarkable for a broad-based gait requiring assistance to walk and bilateral corrective saccades. Vestibular testing revealed high-grade bilateral vestibular loss associated with all semicircular canals, a considerable decline compared to her function 3 years prior. DISCUSSION: Gentamicin is indicated for surgical prophylaxis when a patient has a true allergy to penicillins and cannot receive cephalosporins, though alternatives exist. True allergies include IgE-mediated illness (anaphylaxis, bronchospasm, or urticaria 30-60 minutes after administration) or exfoliative reactions (Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis). The authors encourage more prudent use of gentamicin, especially in patients susceptible for debilitating otologic insults, and offer recommendations for alternative agents prior to using gentamicin.


Subject(s)
Gentamicins , Ototoxicity , Female , Humans , Anti-Bacterial Agents/adverse effects , Gentamicins/adverse effects , Hypersensitivity , Ototoxicity/etiology , Penicillins/adverse effects
2.
Thorac Surg Clin ; 33(1): 109-116, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36372527

ABSTRACT

Pulmonary nodules (lesions <3 cm in size) are commonly identified on computed tomographic scans, but radiographic features alone are inadequate to reliably differentiate between benign and malignant etiologies. Therefore, tissue biopsy remains the standard approach to determine the appropriate treatment course for many patients with pulmonary nodules. Although percutaneous biopsy is highly accurate, it poses substantial risks of procedural complications, including pneumothorax and bleeding. Robotic bronchoscopy has recently been developed to overcome many of the limitations of previous navigational platforms. Here, we explore the currently available systems for robotic bronchoscopy-in particular, electromagnetic-navigation robotic-assisted bronchoscopy and shape-sensing robotic-assisted bronchoscopy.


Subject(s)
Lung Neoplasms , Multiple Pulmonary Nodules , Robotic Surgical Procedures , Humans , Bronchoscopy/methods , Robotic Surgical Procedures/methods , Electromagnetic Phenomena , Lung/diagnostic imaging , Lung/pathology , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology
4.
Oncogene ; 39(4): 877-890, 2020 01.
Article in English | MEDLINE | ID: mdl-31570787

ABSTRACT

Barrett's esophagus (BE) is associated with reflux and is implicated the development of esophageal adenocarcinoma (EAC). Apoptosis induces cell death through mitochondrial outer membrane permeabilization (MOMP), which is considered an irreversible step in apoptosis. Activation of MOMP to levels that fail to reach the apoptotic threshold may paradoxically promote cancer-a phenomenon called "Minority MOMP." We asked whether reflux-induced esophageal carcinogenesis occurred via minority MOMP and whether compensatory resistance mechanisms prevented cell death during this process. We exposed preneoplastic, hTERT-immortalized Barrett's cell, CP-C and CP-A, to the oncogenic bile acid, deoxycholic acid (DCA), for 1 year. Induction of minority MOMP was tested via comet assay, CyQuant, annexin V, JC-1, cytochrome C subcellular localization, caspase 3 activation, and immunoblots. We used bcl-2 homology domain-3 (BH3) profiling to test the mitochondrial apoptotic threshold. One-year exposure of Barrett's cells to DCA induced a malignant phenotype noted by clone and tumor formation. DCA promoted minority MOMP noted by minimal release of cytochrome C and limited caspase 3 activation, which resulted in DNA damage without apoptosis. Upregulation of the antiapoptotic protein, Mcl-1, ROS generation, and NF-κB activation occurred in conjunction with minority MOMP. Inhibition of ROS blocked minority MOMP and Mcl-1 upregulation. Knockdown of Mcl-1 shifted minority MOMP to complete MOMP as noted by dynamic BH3 profiling and increased apoptosis. Minority MOMP contributes to DCA induced carcinogenesis in preneoplastic BE. Mcl-1 provided a balance within the mitochondria that induced resistance complete MOMP and cell death. Targeting Mcl-1 may be a therapeutic strategy in EAC.


Subject(s)
Apoptosis , Barrett Esophagus/pathology , Bile Acids and Salts/pharmacology , Carcinogenesis/pathology , Esophageal Neoplasms/pathology , Mitochondria/pathology , Myeloid Cell Leukemia Sequence 1 Protein/metabolism , Barrett Esophagus/drug therapy , Barrett Esophagus/genetics , Barrett Esophagus/metabolism , Carcinogenesis/chemically induced , Carcinogenesis/genetics , Carcinogenesis/metabolism , Cell Line , Cell Membrane Permeability , Cytochromes c/metabolism , DNA Damage , Esophageal Neoplasms/drug therapy , Esophageal Neoplasms/genetics , Esophageal Neoplasms/metabolism , Esophagus/drug effects , Esophagus/metabolism , Esophagus/pathology , Gastrointestinal Agents/pharmacology , Humans , Mitochondria/drug effects , Mitochondria/metabolism , Signal Transduction
5.
Discov Med ; 26(142): 85-92, 2018 09.
Article in English | MEDLINE | ID: mdl-30399326

ABSTRACT

A growing understanding of the immune system and its anti-tumor functions has been imperative for the comprehension of malignant processes and beneficial in the pursuit of effective cancer treatments. To defend the body, immune cells must be able to differentiate between self and foreign cells using checkpoints, allowing the immune cells to attack foreign cells. Among the different types of immune target therapies recently developed, checkpoint inhibitors have come to the forefront in cancer treatment, encouraging their study in numerous different types of cancer, including hepato-pancreato-biliary malignancies (HPB). Traditionally, these malignancies have been treated with standard cytotoxic chemotherapy, but with little benefit in the metastatic setting. However, impressive results with checkpoint inhibitor therapy have been noted in a number of cancers as these agents enable immune cells to kill cancer cells more efficiently. Two classes of checkpoint inhibitors being extensively studied are inhibitors of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) ligand and programmed cell death protein 1 and its ligand (PD-1 and PD-L1). Checkpoint inhibitors have an advantage over other types of immunotherapies, such as cell-based therapies, in that they are commercially available and can be given to patients with a range of pathologies and regardless of HLA status. Herein, we will discuss the application of immune checkpoint inhibitors to HPB malignancies as well as the limitations of these medications in these cancers.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Biliary Tract Neoplasms/therapy , Cell Cycle Checkpoints , Liver Neoplasms/therapy , Pancreatic Neoplasms/therapy , Protein Kinases/therapeutic use , B7-H1 Antigen/immunology , Biliary Tract Neoplasms/immunology , CTLA-4 Antigen/immunology , Cell Cycle Checkpoints/immunology , Humans , Immunotherapy/adverse effects , Immunotherapy/methods , Liver Neoplasms/immunology , Pancreatic Neoplasms/immunology , Programmed Cell Death 1 Receptor/immunology
6.
Mol Cancer Ther ; 17(9): 2013-2023, 2018 09.
Article in English | MEDLINE | ID: mdl-29934340

ABSTRACT

In 2017, an estimated 17,000 individuals were diagnosed with esophageal adenocarcinoma (EAC), and less than 20% will survive 5 years. Positron emission tomography avidity is indicative of high glucose utilization and is nearly universal in EAC. TXNIP blocks glucose uptake and exhibits proapoptotic functions. Higher expression in EAC has been associated with improved disease-specific survival, lack of lymph node involvement, reduced perineural invasion, and increased tumor differentiation. We hypothesized that TXNIP may act as a tumor suppressor that sensitizes EAC cells to standard chemotherapeutics. EAC cell lines and a Barrett epithelial cell line were used. qRT-PCR, immunoblot, and immunofluorescence techniques evaluated gene expression. TXNIP was stably overexpressed or knocked down using lentiviral RNA transduction techniques. Murine xenograft methods examined growth following overexpression of TXNIP. Apoptosis and DNA damage were measured by annexin V and γH2AX assays. Activation of the intrinsic apoptosis was quantitated with green fluorescence protein-caspase 3 reporter assay. In cultured cells and an esophageal tissue array, TXNIP expression was higher in Barrett epithelia and normal tissue compared with EAC. Constitutive overexpression of TXNIP decreased proliferation, clonogenicity, and tumor xenograft growth. TXNIP overexpression increased, whereas knockdown abrogated, DNA damage and apoptosis following cisplatin treatment. An HDAC inhibitor, entinostat (currently in clinical trials), upregulated TXNIP and synergistically increased cisplatin-mediated DNA damage and apoptosis. TXNIP is a tumor suppressor that is downregulated in EACC. Its reexpression dramatically sensitizes these cells to cisplatin. Our findings support phase I/II evaluation of "priming" strategies to enhance the efficacy of conventional chemotherapeutics in EAC. Mol Cancer Ther; 17(9); 2013-23. ©2018 AACR.


Subject(s)
Adenocarcinoma/drug therapy , Apoptosis/drug effects , Benzamides/pharmacology , Carrier Proteins/genetics , DNA Damage , Esophageal Neoplasms/drug therapy , Pyridines/pharmacology , Xenograft Model Antitumor Assays , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Apoptosis/genetics , Carrier Proteins/metabolism , Cell Line, Tumor , Cisplatin/administration & dosage , Esophageal Neoplasms/genetics , Esophageal Neoplasms/metabolism , Female , Gene Expression Regulation, Neoplastic/drug effects , Histone Deacetylase Inhibitors/pharmacology , Humans , Mice, Nude , Transcriptional Activation/drug effects
8.
Clin Infect Dis ; 66(9): 1427-1434, 2018 04 17.
Article in English | MEDLINE | ID: mdl-29145578

ABSTRACT

Background: Chronic granulomatous disease (CGD) is a rare genetic disorder causing recurrent infections. More than one-quarter of patients develop hepatic abscesses and liver dysfunction. Recent reports suggest that disease-modifying treatment with corticosteroids is effective for these abscesses. Comparison of corticosteroid therapy to traditional invasive treatments has not been performed. Methods: Records of 268 patients with CGD treated at the National Institutes of Health from 1980 to 2014 were reviewed. Patients with liver involvement and complete records were included. We recorded residual reactive oxygen intermediate (ROI) production by neutrophils, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase germline mutation status, laboratory values, imaging characteristics, time to repeat hepatic interventions, and overall survival among 3 treatment cohorts: open liver surgery (OS), percutaneous liver-directed interventional radiology therapy (IR), and high-dose corticosteroid management (CM). Results: Eighty-eight of 268 patients with CGD suffered liver involvement. Twenty-six patients with a median follow-up of 15.5 years (8.5-32.9 years of follow-up) had complete records and underwent 100 standard interventions (42 IR and 58 OS). Eight patients received a treatment with high-dose corticosteroids only. There were no differences in NADPH genotype, size, or number of abscesses between patients treated with OS, IR, or CM. Time to repeat intervention was extended in OS compared with IR (18.8 vs 9.5 months, P = .04) and further increased in CM alone (median time to recurrence not met). Impaired macrophage and neutrophil function measured by ROI production correlated with shorter time to repeat intervention (r = 0.6, P = .0019). Conclusions: Treatment of CGD-associated liver abscesses with corticosteroids was associated with fewer subsequent hepatic interventions and improved outcome compared to invasive treatments.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Granulomatous Disease, Chronic/complications , Liver Abscess/etiology , Neutrophils/cytology , Adolescent , Adult , Child , Child, Preschool , Disease Management , Female , Granulomatous Disease, Chronic/drug therapy , Humans , Infant , Infant, Newborn , Liver/microbiology , Liver/pathology , Liver/surgery , Liver Abscess/drug therapy , Liver Abscess/microbiology , Male , Medical Records , NADPH Oxidases/analysis , Recurrence , Treatment Outcome , Young Adult
10.
Cancer Res ; 77(22): 6267-6281, 2017 11 15.
Article in English | MEDLINE | ID: mdl-28935813

ABSTRACT

In this study, we generated induced pluripotent stem cells (iPSC) from normal human small airway epithelial cells (SAEC) to investigate epigenetic mechanisms of stemness and pluripotency in lung cancers. We documented key hallmarks of reprogramming in lung iPSCs (Lu-iPSC) that coincided with modulation of more than 15,000 genes relative to parental SAECs. Of particular novelty, we identified the PRC2-associated protein, ASXL3, which was markedly upregulated in Lu-iPSCs and small cell lung cancer (SCLC) lines and clinical specimens. ASXL3 overexpression correlated with increased genomic copy number in SCLC lines. ASXL3 silencing inhibited proliferation, clonogenicity, and teratoma formation by Lu-iPSCs, and diminished clonogenicity and malignant growth of SCLC cells in vivo Collectively, our studies validate the utility of the Lu-iPSC model for elucidating epigenetic mechanisms contributing to pulmonary carcinogenesis and highlight ASXL3 as a novel candidate target for SCLC therapy. Cancer Res; 77(22); 6267-81. ©2017 AACR.


Subject(s)
Epithelial Cells/metabolism , Induced Pluripotent Stem Cells/metabolism , Lung Neoplasms/genetics , Small Cell Lung Carcinoma/genetics , Transcription Factors/genetics , Animals , Cell Line, Tumor , Cells, Cultured , Cellular Reprogramming , Epigenesis, Genetic , Gene Expression Profiling/methods , Humans , Induced Pluripotent Stem Cells/transplantation , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Respiratory Mucosa/cytology , Small Cell Lung Carcinoma/metabolism , Small Cell Lung Carcinoma/pathology , Teratoma/genetics , Teratoma/metabolism , Transcription Factors/metabolism , Transplantation, Heterologous
11.
Transl Lung Cancer Res ; 6(3): 350-365, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28713680

ABSTRACT

Malignant pleural mesotheliomas (MPM) are notoriously refractory to conventional treatment modalities. Recent insights regarding epigenetic alterations in MPM provide the preclinical rationale for the evaluation of novel combinatorial regimens targeting the epigenome in these neoplasms.

14.
J Phys Chem B ; 114(38): 12398-405, 2010 Sep 30.
Article in English | MEDLINE | ID: mdl-20815360

ABSTRACT

Ultrafast transient absorption spectroscopy was used to investigate the photochemistry of adenosylcobalamin (AdoCbl), methylcobalamin (MeCbl), and n-propylcobalamin (PrCbl) at pH 2 where the axial nitrogenous ligand is replaced by a water molecule. The evolution of the difference spectrum reveals the internal conversion process and spectral characteristics of the S(1) excited state. The photolysis yield in the base-off cobalamins is controlled by competition between internal conversion and bond homolysis. This is in direct contrast to the process in most base-on alkylcobalamins where primary photolysis occurs with near unit quantum yield and the photolysis yield is controlled by competition between diffusive separation of the radical pair and geminate recombination. The absence of the axial nitrogenous ligand in the base-off cobalamins modifies the electronic structure and opens a channel for fast nonradiative decay. This channel competes effectively with the channel for bond dissociation, dropping the quantum yield for primary radical pair formation from unity in base-on PrCbl and AdoCbl to 0.2 ± 0.1 and 0.12 ± 0.06 in base-off PrCbl and AdoCbl, respectively. The photolysis of base-off MeCbl is similar to that of base-off AdoCbl and PrCbl with competition between rapid nonradiative decay leading to ground state recovery and formation of a radical pair following bond homolysis.


Subject(s)
Cobamides/chemistry , Molecular Dynamics Simulation , Quantum Theory , Vitamin B 12/analogs & derivatives , Hydrogen-Ion Concentration , Ligands , Molecular Conformation , Photochemistry , Photolysis , Spectrophotometry, Ultraviolet , Time Factors , Vitamin B 12/chemistry , Water/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...